R. L. R. Costa

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

G. Krogh, R. Railkar, M. Lehtinen, 2006, British Journal of Cancer.

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.

M. Lehtinen, A. Saah, G. von Krogh, 2007, Vaccine.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Cosette M Wheeler, Diane M Harper, Mark H Stoler, 2005, The Lancet. Oncology.

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

C. Wheeler, R. Railkar, M. Lehtinen, 2006, Vaccine.